Repositioning Candidate Details

Candidate ID: R0498
Source ID: DB01347
Source Type: experimental
Compound Type: small molecule
Compound Name: Saprisartan
Synonyms: Saprisartan
Molecular Formula: C25H22BrF3N4O4S
SMILES: CCC1=NC(C2CC2)=C(N1CC1=CC2=C(OC(=C2Br)C2=CC=CC=C2NS(=O)(=O)C(F)(F)F)C=C1)C(N)=O
Structure:
DrugBank Description: Saprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure. The mode of (functional) AT1 receptor antagonism has been characterized as insurmountable/noncompetitive for saprisartan. It is very likely that slow dissociation kinetics from the AT1 receptor underlie insurmountable antagonism .
CAS Number: 146623-69-0
Molecular Weight: 611.431
DrugBank Indication: Saprisartan is used in the treatment of hypertension and heart failure.
DrugBank Pharmacology: By inhibiting the angiotensin II receptor, this drug leades to a decrease in sodium reabsorption and a decrease in vasoconstriction. This has the combined effect of decreasing blood pressure.
DrugBank MoA: Saprisartan is a selective, potent, orally active and long-acting nonpeptide Angiotensin II type 1 (AT1) receptor antagonist. Saprisartan blocks the renin-angiotensin-aldosterone system (RAAS) at the level of the AT1 receptor that mediates most, if not all, of the important actions of Ang II. Saprisartan binds reversibly to the AT1 receptors in vascular smooth muscle and the adrenal gland. As angiotensin II is a vasoconstrictor, which also stimulates the synthesis and release of aldosterone, blockage of its effects results in decreases in systemic vascular resistance. AT1 receptor antagonists avoid the nonspecificity of the Ang I converting enzyme (ACE) inhibitors.
Targets: Type-1 angiotensin II receptor antagonist
Inclusion Criteria: Target associated